NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to heal scarred livers in common disease
Disease control CompletedThis study tested whether a drug called saroglitazar magnesium could help people with a serious form of fatty liver disease called NASH, which causes liver scarring. 189 adults with confirmed NASH and moderate scarring took either the drug or a placebo pill for 52 weeks. The main…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Apr 02, 2026 09:26 UTC
-
Drug combo tested to reverse scarring in advanced fatty liver disease
Disease control CompletedThis study tested whether two different drug combinations could improve liver scarring and reduce inflammation in people with advanced liver disease caused by NASH, a serious form of fatty liver disease. It involved 457 participants with compensated cirrhosis. The goal was to see…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Targeted genetic therapy tested for common liver disease
Disease control CompletedThis study tested an investigational injection called AZD2693 to see if it could treat NASH, a type of fatty liver disease that causes scarring. It specifically enrolled 220 adults with NASH and liver scarring who carry a certain gene (PNPLA3 148M) that increases their risk. The …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug shows promise against silent liver disease
Disease control CompletedThis study tested whether the drug efinopegdutide could help adults with nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Researchers compared the drug against a placebo in 381 participants over 52 weeks to see if it could clear liver inflammation witho…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Common vitamin tested to fight silent liver disease
Disease control CompletedThis study aimed to find the best dose of Vitamin E to help adults with nonalcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver. Researchers tested three different doses of Vitamin E against a placebo in 200 participants over 24 weeks. The main goal…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC